BioMarin Pharmaceutical (BMRN) Gets a Buy Rating from Credit Suisse

By Austin Angelo

Credit Suisse analyst Martin Auster maintained a Buy rating on BioMarin Pharmaceutical (BMRNResearch Report) yesterday and set a price target of $128.00. The company’s shares closed last Wednesday at $120.23.

According to, Auster is a 5-star analyst with an average return of 16.1% and a 56.0% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $128.74, a 7.3% upside from current levels. In a report issued on July 24, Robert W. Baird also maintained a Buy rating on the stock with a $140.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $131.95 and a one-year low of $62.88. Currently, BioMarin Pharmaceutical has an average volume of 1.45M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.